The Curative Effect Observation Of Bortezomib Combined With Dexamethasone To Treat Multiple Myeloma

Objective:To evaluate the therapeutic effect and adverse events of bortezomibcombined with dexamethasone to treat multiple myeloma (MM).Method:Total of 16 MM patients (since 2006) were received the treatme ofbortezomib(1.0 -1.3mg/m~2 by iv push on days 1,4,8, and11) combined withdexamethasone 20mg on the days 1 to2, 4 to 5, 8 to 9 and 11 to 12) in a 3-weekscycle, a total of six treatment cycles were allowed.Response to bortezomib wasevaluated according to the criteria Adverse events were graded according to theNational Cancer Institute Common Toxicity Criteria.Result: After one cycle clinical response was observed that total effective rate is68.75% . When When all treat distance be over , 3 patients were completeemission(CR) , 5 were near CR(nCR) , 4 were partial remission(PR) , 2 minorremission (MR), 2 were no remission (NR). CR+nCR+PR reached to 75%.It is safetyto treat in the patient with renal failure,and probable has theefect with boneremodeling.The drug-related toxicities have been encountered are thrombocytopenia(9/16), fatigue (6/16), tricks numb(2/16), dermatoallergic reaction(1/16), 15),herpeszoster virus(HZV) infection(2/15), diarrhoea(1/16),but all the adverse reaction wererelieved or recovered after drug withdrawal.Conclusion: Bortezomib combined with dexamethasone to treat multiplemyeloma(MM) is safety and effective.The adverse reaction is light and reversible. Itis worthy for clinical widespread generalization.